Agios Pharmaceuticals (AGIO) stock

Market cap $1.9B

$33.42

+2.58%

Market closed. Prices as of Monday's close.

Quality Score

Below Average

In its industry

#73of 260

Biotech

Checks firing

3of 14

Choppy

From 52-week high

-27.3%

Above the 200-day

NextNov 1, 2026 FDA decision date“sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026”8-K, Jul 30

Cash$618M, about 6 quarters at the last year's spendingOn Jun 30

Follow AGIO's trial news. Members get an alert when Agios Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AGIO files news on its trials8 days free. No card.

Cash$618M, about 6 quarters at the last year's spendingOn Jun 30

Pipeline and cash

What's next for AGIO, and how long its cash lasts

From Agios Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Nov 1“sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026”FDA decision date · 8-K, Jul 30

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

For members: 14 trials underway, 2 more milestones, and 23 filings.

Cash runway to Jun 30

About 6 quarters

$618M in cash ÷ $90.1M used a quarter over the last year

What it means: how long the cash would last at the same pace, before any new money.

For members: the share count, 1 shelf filing, and the math.

Brian GoffChief Executive OfficerFrom their own Form 4 filings

For members: their 12 filings and quotes, and an alert each time they file.

Get an alert when AGIO files news on its trials8 days free. No card.

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.

MRKMerck · $367BOct 4FDA date13
IONSIonis Pharmaceuticals · $7.4BOct 26FDA date-4
INOInovio Pharmaceuticals · $122MOct 30FDA date-7

58 more companies with an FDA date or a trial due in these 60 days. Members see every one, with its score and cash runway, sorted by date.Get in free →

Quality Score

Why AGIO scores 4

Below AverageChoppy, 3 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+3Momentum traits 3 of 14 firing right now, one point each
+3Growth sales up 141% on the year, gross margin up 3.8 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Run-up, Size, Dilution, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on AGIO and every other stock.Get in free →

Price, score, traits, and the industry rank are from a snapshot taken at 1:00 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Thu Oct 29, before the open

After its last 4 reports it closed +2.7% on average, higher 3 of 4 times.

What would turn AGIO's score around: 6 things, for members

Alert me when AGIO's Quality Score turns up

8 days free. No card. No account needed today.

For members

Here is what members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the momentum bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A member's stock page for AMD: the price, the Quality Score, the rank, the traits firing, relative strength, and the chart — A stock page

The scanner a member sees: every stock as a card with its Quality Score, rank, and momentum bar, the watchlist, and the day's top gainers — The scanner

The 14 checks

AGIO has 3 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on AGIO, and all 14 on every stock.Get in free →

Its industry

How AGIO ranks in Biotech

AGIO is #73 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.

1RGENRepligen9/1421
2ABCLAbCellera Biologics10/1420
3XERSXeris Biopharma Holdings9/1419
HALOHalozyme TherapeuticsOpen for its score
ONCBeOne MedicinesOpen for its score
73AGIOAgios Pharmaceuticals3/144

More in Biotech, on the Healthcare page →

Earnings

When does AGIO report, and what happens after?

Expected to report Thu Oct 29, before the open (in 30 days). Not yet confirmed by the company.

+2.9%+1.3%+13.1%-6.5%

Oct 30Feb 12Apr 29Jul 30

Reported	When	Gap	Reaction	5 sessions
Jul 30, 2026Before open	Before open	-15.8%	-6.5%	-9.4%
Apr 29, 2026Before open	Before open	+6.8%	+13.1%	+9.7%
Feb 12, 2026Before open	Before open	+0.5%	+1.3%	+3.1%
Oct 30, 2025Before open	Before open	+0.5%	+2.9%	-3.5%

The gap is the next open against the close before the report; the reaction is where that session closed. AGIO closed higher after 3 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Filings

Who is trading AGIO

Congress and the White House

One trade disclosed in the last six months. The newest:

BuyGilbert Cisneros$1K to $15KHousetraded Aug 20, disclosed Sep 10(21 days later)

BuyGilbert CisnerosHouse$1K to $15Ktraded Aug 20, disclosed Sep 10(21 days later)

Congress gets 45 days to report a trade, so the two dates are weeks apart. Shown as filed, with no delay.

See what Congress is buying across the market →

The company

About Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

540 employeesCambridge, MAagios.com

For members

Every line of the score, on every stock.

Real-time prices, no delay
Every line of AGIO's score, with the points and the reason
All 14 checks on AGIO and on all 2,950 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on AGIO

BreakawaySep 10Gilbert Cisneros bought AGIO$1K to $15K, disclosed Sep 10

What a filing on AGIO would have sent. Alerts are optional.

See all 14 checks on AGIO8 days free. No card. No account needed today.

Questions

Straight answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.

What does it cost?

Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.